Corticoids: Their use in the pathology of the oral mucosa;Corticoides: Su uso en patología de la mucosa oral

Medicina Oral

Volumn 8, Issue 4, 2003, Pages 248-259

  Llamas Martínez, Silvia ^a,b   Esparza Gómez, Germán Carlos ^a   Moreno López, Luis Alberto ^b   Cerero Lapiedra, Rocío ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b UCM ^*

Author keywords

Pathology of the oral mucosa; Therapy with glucocorticoids

Indexed keywords

ALDOSTERONE; BECLOMETASONE DIPROPIONATE; BETAMETHASONE; BETAMETHASONE BENZOATE; BETAMETHASONE DIPROPIONATE; BETAMETHASONE VALERATE; CLOBETASOL BUTYRATE; CLOBETASOL PROPIONATE; CLOTRIMAZOLE; CORTICOSTEROID; CORTISONE; CORTIVAZOL; DEOXYCORTICOSTERONE; DEXAMETHASONE; FLUDROCORTISONE; FLUMETASONE PIVALATE; FLUOCINOLONE ACETONIDE; FLUOCINONIDE; FLUPREDNISOLONE; HYDROCORTISONE; HYDROCORTISONE BUTYRATE; METHYLPREDNISOLONE; MOMETASONE FUROATE; OROBASE; PARAMETHASONE; PREDNISOLONE; PREDNISONE; PREDNYLIDENE; TRIAMCINOLONE; TRIAMCINOLONE ACETONIDE; UNINDEXED DRUG;

CORTICOSTEROID THERAPY; DRUG HYPERSENSITIVITY; ENDOCRINE DISEASE; GROWTH INHIBITION; HUMAN; MOUTH DISEASE; MOUTH MUCOSA; PEMPHIGUS VULGARIS; PRACTICE GUIDELINE; REVIEW; SIDE EFFECT; TOPICAL TREATMENT;

ADRENAL CORTEX HORMONES; HUMANS; MOUTH DISEASES; MOUTH MUCOSA;

EID: 0041519053     PISSN: 11372834     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (74)

1. Sánchez P, Sánchez EF. Corticoides naturales y sintéticos. En: B. Lorenzo Velázquez. Farmacología y su proyección a la clínica. Madrid: Ed. Oteo; 1987. p. 721-35.
2. Quintana A, Raczka E. Bases farmacológicas. En: Bascones A, Bullón P, Castillo JR, Machuca G, Serrano JS. Bases farmacológicas de la terapéutica dental. Madrid: Ed. Avance; 2000. p. 175-208.
3. Cerero R, Esparza G, En Bascones A, Llanes F. Corticoides y otras terapéuticas en Medicina Bucal. Medicina Bucal. Madrid: Ed. Avances; 1996. p.775-92.
4. Planas ME, Sánchez S. Farmacología de la inflamación. En: Espulgues J, Morcillo EJ, De Andrés-Trelles F. Farmacología en Clínica Dental. Barcelona: Ed. JR Prous Editores; 1993. p. 155-79.
5. Gersema L, Baker K. Use of corticosteroids in Oral Surgery. J Oral Maxillofac Surg 1992;50:270-7.
6. Bowman WC, Rand MJ. Farmacología. Bases bioquímicas y patológicas. Aplicaciones clínicas. Barcelona: Ed. Interamericana; 1985. p. 1-62.
7. Neidle EA, Kroeger DC, Yogiela JA. Pharmacology and therapeutics for dentistry. St Louis: Ed Mosby; 1985. p. 350-8.
8. Flórez J, Amado JA. Esteroides corticales y antiinflamatorios esteroideos. En: Flórez J. Farmacología humana. Barcelona: Ed. Masson Salvat; 1994. p. 813.
9. Miller JA, Munro DD. Topical Corticosteroids: Clinical Pharmacology and Therapeutic Use. Drugs 1980;19:119-34.
10. Haynes R, Murad P. Adrenocorticotropic hormone: adrenocortical steroids and their synthetic analysis; Inhibitors of adrenocortical steroids biosíntesis. En: Goodman A, Goodman L, Theodore W, Murad F. Goodman and Gilman's. The pharmacological Basis of therapeutics. Ed Macmillan; 1985. p. 1459-89.
11. Lozada F, Silverman S, Migliorati C. Adverse side effects associated with prednisone in the treatment of patients with oral inflamatory ulcerative diseases. J Am Dent Assoc 1984;109:269-70.
12. Lamey Pj, Rees TD, Binnie WH, Wright JM, Rankin KV, Simpson WB. Oral presentation of pemphigus vulgaris and its response to systemic steroid therapy. Oral Surg Oral Med Oral Pathol 1992;74:54-7.
13. López P, Bermejo A. Enfermedades que cursan con úlceras, vesículas y ampollas en la mucosa bucal. En: Bascones y cols. Tratado de Odontología. Madrid: Ed SmithKline Beecham; 1998. p. 3007-24.
14. Pedersen A, Klausen B. Glucocorticosteroids and oral medicine. J Oral Pathol 1984;4:1-15.
15. Kay W. Corticosteroids in diseases of the oral mucosa. Int Dent J 1976;26:405-10.
16. Kalmar J. Topical corticosteroids and oral vesiculo-erosive disease: Where's the beef? Oral Surg Oral Med Oral Pathol 2000;89:395-6.
17. Castellano S, Carozzo M, Gandolfo S. Systemic corticosteroid in the treatment of oral vesiculoerosive disease. J Dent Res (IADR abstracts) 1998;77:747.
18. Vincent SD, Fotos PG, Baker KA, Williams TP. Oral lichen planus: the clinical, historical and therapeutics features of 100 cases. Oral Surg Oral Med Oral Pathol 1990;70:165-71.
19. Vincent SD, Lilly GE. Clinical, historic, and therapeutic features of aphthous stomatitis. Oral Surg Oral Med Oral Pathol 1992;74:79-86.
20. Vincent SD, Lilly GE, Baker KA. Clinical, historic, and therapeutic features of cicatricial pemphigus. A literature review and open therapeutic trial with corticosteroids. Oral Surg Oral Med Oral Pathol. 1993;74:453-9.
21. Carrozzo M, Gandolfo S. The management of oral lichen planus. Oral Dis 1999;5:196-205.
22. Bermejo A. Lupus eritematoso. II: Pronóstico, tratamiento, evolución y manejo estomatológico. Av Odontoestomatol 1991;7:541-7.
23. Robinson J, Lozada-Nur F, Frieden I. Oral pemphigus vulgaris: a review of the literature and a report in the management of 12 cases. Oral Surg Oral Med Oral Pathol Oral Rad End 1997;84:349-55.
24. Bagán JV. Enfermedades ampollares de la cavidad oral (I): pénfigos. En: Bagán JV, Ceballos A, Bermejo A, Aguirre JM, Peñarrocha M. Medicina Oral. Barcelona: Ed. Masson; 1995. p. 135-50.
25. Milián Ma A, Jiménez Y. Enfermedades ampollares de la cavidad oral: pénfigo y penfigoide. RCOE 1997;2:633-41.
26. McCreary CE, McCartan BE. Clinical management of oral lichen planus. Br J of Oral and Maxillofac Surg 1999;37:338-43.
27. Mignogna M, Lo Muzio L, Mignogna R, Carbone R, Ruoppo E, Bucci E. Oral pemphigus: long term behaviour and clinical reponse to treatment with deflazacort in sixteen patients. J Oral Pathol Med 2000;29:145-52.
28. Mignogna MD, Lo Muzio L, Bucci E. Clinical features of gingival pemphigus vulgaris. J Clin Periodontol 2001;28:489-93.
29. Roujeau JC. Pulse Glucocorticoid Therapy. The 'Big Shot' Revisited. Arch Dermatol 1996;132:1499-502.
30. Khaitan B, Raman R, Chandra M. Dexamethasone-cyclophosphamide pulse therapy for pemphigus. Int J Dermatology 1995;34:875-82.
31. Fine JD, Lewitt M, Green L, Sams M. Pemphigus Vulgaris. Combined Treatment With Intravenous Corticosteroid Pulse Therapy. Plasmapheresis, and Azathioprina. Arch Dermatol 1988;124:236-9.
32. Regezi JA, Sciubba J. Oral Pathology. Clinical-Pathologic Correlations. Philadelphia: Ed. Saunders Co; 1993. p. 1-15.
33. Bagán JV. Enfermedades ampollares de la cavidad oral (III): eritema multiforme, dermatosis IgA lineal, dermatitis herpetiforme y epidermolisis ampollar. En: Bagán JV, Ceballos A, Bermejo A, Aguirre JM. Peñarrocha M. Medicina Oral. Barcelona: Ed. Masson; 1995. p. 234-40.
34. Katz J, Livneh A, Shemer J, Danon Y. Peretz B. Herpes simplex-associated erythema multiforme (HAEM): a clinical therapeutic dilema. Pediatric Dent 1999;21:359-62.
35. Addy M. The oral mucosal absorption and tissue distribution of triamcinolone acetonide in the dog studied by autoradiography. Archs Oral Biol 1980:25:809-17.
36. Addy M, S. J. Pimlott, Thaw M. The oral retention of prednisolone mouthwashes-effects of concentration and time. J Oral Med 1986;41:82-7.
37. Carbone M, Conrotto P, Carrozzo M, Brocaletti R, Gandolfo S, Scully C. Topical corticosteroids in association with miconazole and clorhexidine in the log term management of atrophic-erosive oral lichen planus: a placebo controlled and comparative study between clobetasol and fluocinolone. Oral Dis 1999;5:44-9.
38. Sanchis JM, Jiménez Y. Estomatitis aftosa recidivante: revisión terapéutica. ORIS 1991;4:83-95.
39. Larrea G, Aguirre JM. La gingivitis descamativa crónica. Rev Vasca Odontoestomatol 1996;6:248-55.
40. Ungphaiboon S, Maitani Y. In vitro permeation studies of triamcinolone acetonide mouthwashes. Int J of Pharmaceutics 2001;220:111-7.
41. Lozada F, Silverman S.Jr. Topically applied fluocinonide in an adhesive base in the treatment of oral vesiculoerosive diseases. Arch Dermatol 1980;116:898-901.
42. Rodu B, Russell C. Performance of a hydroxypropyl cellulose film former in normal and ulcerated oral mucosa. Oral Surg Oral Med Oral Pathol 1988;65:699-703.
43. Lo Muzio L, della Valle A, Mignogna M. The treatment of oral aphthous ulceration or erosive lichen planus with topical clobetasol propionate in three preparations: a clinical and pilot study of 54 patients. J Oral Pathol Med 2001;30:611-7.
44. Pisanty S, Azaz E, Segal R. Glycyrrhizin as Vehicle for the application of triamcynolone in the tretment of Recurrent Aphtous Stomatitis. Pharm Act Helv 1984;59:341-4.
45. Ship J, Chavez E, Doerr P, Henson B, Sarmadi M. Recurrent apthous stomatitis. Quintessence Int 2000;31:95-112.
46. Stoughton RB, Wullich K. Relation of application time to bioactivity of potent topical glucocorticoid formulation. J Am Acad dermatol 1990;22:1038-41.
47. Stoughton R, La Jolla C. Vasoconstrictor activity and percutaneous absorption of glucocorticosteroids. A direct comparison. Arch Derm 1969;99:753-6.
48. Stoughton R. Penetration of drugs through the skin. Dermatologica 1976;152:27-36.
49. Thongsprasom K, Luangjarmekorn L, Seretat T, Taweesap W. Relative efficacy of fluocinolone acetonide compared with triamcinolone acetonide in treatment of oral lichen planus. J Oral Pathol Med 1992;21:456-8.
50. Rödström P-O, Hakeberg M, Jontell M, Mordin P. Erosive oral lichen planus treated with clobetasol propionate and triamcinolone acetonide in orabase: a double-bind clinical trial. J Dermatol Treat 1994;5:7-10.
51. López-López J, Roselló X. Cyclosporine A, an alternative to the oral lichen planus eroisive treatment. Bull Group Int Rech Stomatol et Odontol 1995;38:33-7.
52. Sieg P, Von Domarus H, Von Zitzewitz V, Iven H, Färber L. Topical cyclosporin in oral lichen planus: a controlled, randomized, prospective trial. Br J of Dermatol 1995;132:790-4.
53. Miles D, Bricker S, Razuns T, Potter R. Triamcinolone acetonide versus chlorhexidine for treatment of recurrent stomatitis. Oral Surg Oral Med Oral Pathol 1993;75:397-402.
54. Edres MAG, Scully C, Gelbier M. Use of proprietary agents to relieve recurrent aphthous stomatitis. Br Dent J 1997;182:144-6.
55. Buajeeb W, Pobrurksa C, Kraivaphan P. Efficacy of fluocinolone acetonide gel in the treatment of oral lichen planus. Oral Surg Oral Med Oral Pathol Oral Rad Endod 2000;89:42-5.
56. Voute AB, Schullen EA, Langendijk PN, Costéense PJ, Van der Waal I. Fluocinonide in an adhesive base for treatment of oral lichen planus. A double-blind, placebo-controlled clinical study. Oral Surg Oral Med Oral Pathol 1993;75:181-5.
57. Lozada-Nur F, Zhong M. Open preliminary clinical trial of clobetasol propionate ointment in adhesive paste for treatment of chronic oral vesiculoerosive disease. Oral Surg Oral Med Oral Pathol 1991;71:283-7.
58. Carbone M, Carozzo M, Conrotto D, Garzino Demo P, Broccoletti R, Gandolfo S. Il trattamento topico del licehn planus orale atrofico-erosivo con clobetasolo in gel bioadesivo, soluzione di clorexidina e miconalzolo gel orale. Minerva stomatol 1997;46;423-8.
59. Hegarty AM, Hodson TA, Lewsey JD, Porter SR. Fluticasone propionate spray and betamethasone sodium phospate mouth rinse: a randomised crossover study for the treatment of symptomatic oral lichen planus. Oral Surg Oral Med Oral Pathol (Abstracts) 2001;91:415.
60. Aguirre JM, Bagán JV, Rodríguez C, Domínguez-Gil A, Díaz De Rojas F, Ponte A. Efficacy of mometasone furoate microemulsion in the treatment of erosive oral lichen planus: pilot study. Oral Surg Oral Med Oral Pathol (Abstracts) 2001;91:418.
61. Scully C, Carrozo M, Gandolfo S, Puiatti P, Monteil R. Update on mucous membrane pemphigoid. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999;88:56-68.
62. Lehner T, Lyne C. Adrenal function during topical oral corticosteroid treatment. Br Dent Journal 1969;4:138-141.
63. Lehner T, Lyne C. Adrenal function during topical oral treatment with triamcinolone acetonide. Br Dent J 1970;129:164-7.
64. Rasmussen JE. Percutaneous absorption of topically applied triamcinolone in children. Arch Dermatol 1978;114:1165-7.
65. Williamson LW, Lorson EL, Sobón DB. Hypothalamic-pituitary-adrenal suppression after shrto-term dexamethasone therapy for oral procedures. J Oral Surg 1980;38:20-8.
66. Lozada-Nur F, Miranda C, Maliski R. Double-blind clinical trial of 0,05% clobetasol propionate oinment in orabase and 0,05% fluocinonide ointment in orabase in the treatment of patients with oral vesiculoerosive diseases. Oral Surg Oral Med Oral Pathol 1994;77:598-604.
67. Ellepola ANB, Samaranayake LP. Inhalational and topical steroids, and oral candidosis: a mini review. Oral Dis 2001;7:211-6.
68. Chainani-Wu N, Silverman Jr, Lozada-Nur F, Watson J. Oral lichen planus. Patient profile, disease progression and treatment responses. J Am Dent Assoc 2001;132:901-9.
69. Alcántara M, Martínez J, López JD, Frías J, Pagán JA. Dermatitis de contacto por corticoides. Manejo clínico. Alergol Inmunol Clin 1999;14:152-5.
70. Bircher AJ, Pelloni F, Langauer S, Müller D. Delayed hypersensitivity reactions to corticosteroids applied to mucous membranes. Br J Dermatol 1996;135:310-3.
71. Firooz A, Tehranchi Z, Ahmed A. Benefits and risks of intralesional corticosteroid injection in the treatment of dermatological diseases. Clinical and Experimental Dermatology 1995;20:363-70.
72. Dusek J, Fiek W. Iichen planus: oral manifestations and suggests treatments. J Oral Maxillofac Surg 1982;40:240-4.
73. Rassasen L, Hasan T. Allergy to systemic and intralesional corticosteroids. Br J Dermatol 1993;128:407-11.
74. Williams P, Greenberg M. Management of cheilitis granulomatosa. Oral Surg Oral Med Oral Pathol 1991;72:436-9.